← Leaderboards
Adam Mor
Columbia University Health Sciences
$8,044,456
Attributed
$9,139,899
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,139,899 · 4
By mechanism
R01$8,779,044 · 3
R21$360,855 · 1
Top collaborators
- Robert Winchester3 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Robert Winchester$7,903,822
- Yufeng Shen$10,499,570
- Kelli Stidham Hall$5,210,174
- Stavroula Kousteni$21,735,971
- Ila R Singh$2,478,781
Others in their field
Top investigators on “Cancer Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,605,292
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- Leonard Freedman · Leidos Biomedical Research, Inc.$66,901,020
- Charles A Coltman · Southwest Oncology Group$64,795,252
- Norman Wolmark · Nsabp Foundation, Inc.$63,442,676
Research focus
Cancer ImmunotherapyImmune SystemT-LymphocyteMolecularMalignant NeoplasmsPathway InteractionsTumorExperimental StudyMediatingAntibodiesCheckpoint TherapyBlocking AntibodiesClinical TrialsSignal TransductionReceptorImmunotherapyImmuneCytoplasmic TailLigand BindingIn VivoNeoplastic CellCancer CellCellsImmune Response
Grant awards (20)
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events$715,543
R01 · FY2025 · AI · contact PI
Novel mechanisms regulating PD-1 signaling and function$441,015
R01 · FY2025 · AI · contact PI
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events$737,672
R01 · FY2024 · AI · contact PI
PAG is a novel target in immunotherapy$539,081
R01 · FY2024 · AI · contact PI
Novel mechanisms regulating PD-1 signaling and function$448,861
R01 · FY2024 · AI · contact PI
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events$737,672
R01 · FY2023 · AI · contact PI
PAG is a novel target in immunotherapy$540,458
R01 · FY2023 · AI · contact PI
Novel mechanisms regulating PD-1 signaling and function$448,417
R01 · FY2023 · AI · contact PI
PAG is a novel target in immunotherapy$520,485
R01 · FY2022 · AI · contact PI
Novel mechanisms regulating PD-1 signaling and function$442,212
R01 · FY2022 · AI · contact PI
PAG is a novel target in immunotherapy$558,683
R01 · FY2021 · AI · contact PI
PAG is a novel target in immunotherapy$583,390
R01 · FY2020 · AI · contact PI
Novel mechanisms regulating PD-1 signaling and function$405,000
R01 · FY2020 · AI · contact PI
(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockade$98,415
R21 · FY2020 · CA · contact PI
Novel mechanisms regulating PD-1 signaling and function$405,000
R01 · FY2019 · AI · contact PI
(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockade$262,440
R21 · FY2019 · CA · contact PI
Novel mechanisms regulating PD-1 signaling and function$339,009
R01 · FY2018 · AI · contact PI
Novel mechanisms regulating PD-1 signaling and function$69,046
R01 · FY2018 · AI · contact PI
Novel mechanisms regulating PD-1 signaling and function$423,750
R01 · FY2017 · AI · contact PI
Novel mechanisms regulating PD-1 signaling and function$423,750
R01 · FY2016 · AI · contact PI